Efficacy and Safety of Lonigutamab in Subjects With Thyroid Eye Disease (TED)

Completed · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Thyroid Eye Disease

In brief

Phase 1/2, multicenter, multiple dose clinical study designed to evaluate lonigutamab in subjects with TED.

Key facts

Study ID

NCT05683496

Run by

ACELYRIN Inc.

People needed

31

Starts

2023-02-14

Expected to finish

2025-05-26

Last updated by the study team

2025-07-01

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Clinical Research Site — Jacksonville, Florida, United States
• Clinical Research Site — Atlanta, Georgia, United States
• Clinical Research Site — Ann Arbor, Michigan, United States
• Clinical Research Site — East Setauket, New York, United States
• Clinical Research Site — New York, New York, United States
• Clinical Research Site — Morgantown, West Virginia, United States
• Clinical Research Site — Sydney, New South Wales, Australia
• Clinical Research Site — Woolloongabba, Queensland, Australia
• Clinical Research Site — Adelaide, South Australia, Australia
• Clinical Research Site — East Melbourne, Victoria, Australia
• Clinical Research Site — Nedlands, Western Australia, Australia

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.